ANIX

Anixa Biosciences, Inc. [ANIX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANIX Stock Summary

Top 10 Correlated ETFs

ANIX


Top 10 Correlated Stocks

ANIX


In the News

04:05 11 Dec 2023 ANIX

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.

11:02 11 Dec 2023 ANIX

FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y

FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

01:32 11 Dec 2023 ANIX

ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10:11 11 Dec 2023 ANIX

The 3 Most Undervalued Cheap Stocks to Buy in September 2023

The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy's ability to recover from the recession without causing significant harm to the job market or sparking excessive inflation. She believes that the United States will successfully navigate this economic challenge, maintaining control over consumer-price increases.This is leading to many investors considering cheap stocks to buy.

01:21 11 Dec 2023 ANIX

What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11:32 11 Dec 2023 ANIX

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

07:13 11 Dec 2023 ANIX

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

12:55 11 Dec 2023 ANIX

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

10:32 11 Dec 2023 ANIX

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

08:30 11 Dec 2023 ANIX

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

ANIX Financial details

Company Rating
Buy
Market Cap
126.77M
Income
-10.06M
Revenue
2.47B
Book val./share
0.82
Cash/share
0.82
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
03 Jan 2024
P/E
-12.56
Forward P/E
-11.3
PEG
4.54
P/S
0.05
P/B
4.95
P/C
5.1
P/FCF
-21.73
Quick Ratio
13.93
Current Ratio
14.22
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.33
EPS next Y
-0.37
EPS next Q
-0.09
EPS this Y
-2.22%
EPS next Y
13.67%
EPS next 5Y
-1261.29%
EPS last 5Y
-11.05%
Revenue last 5Y
366.92%
Revenue Q/Q
-
EPS Q/Q
23.25%
-
-
-
-
SMA20
33.33%
SMA50
33.33%
SMA100
-
Inst Own
7.42%
Inst Trans
0.64%
ROA
-38%
ROE
-37%
ROC
-0.47%
Gross Margin
100%
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
31.07M
Shs Float
29.6M
-
-
-
-
Target Price
8
52W Range
2.75-6.45
52W High
-30.34%
52W Low
+108.99%
RSI
71
Rel Volume
8.14
Avg Volume
93.56K
Volume
761.88K
Perf Week
27.82%
Perf Month
31.03%
Perf Quarter
28.21%
Perf Half Y
22.22%
-
-
-
-
Beta
0.93
-
-
Volatility
0.21%, 0.4%
Prev Close
2.45%
Price
4.1798
Change
16.75%

ANIX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-10-31

Metric History 2018-10-312019-10-312020-10-312021-10-31 2022-10-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.060.0100.0281.29
Net income per share
-0.79-0.61-0.46-0.45-0.44
Operating cash flow per share
-0.24-0.24-0.28-0.17-0.21
Free cash flow per share
-0.24-0.25-0.28-0.17-0.21
Cash per share
0.290.30.411.250.98
Book value per share
0.310.260.391.240.96
Tangible book value per share
0.250.240.371.220.93
Share holders equity per share
0.310.260.391.240.96
Interest debt per share
0000.010.01
Market cap
71.38M76.59M45.79M145.47M170.09M
Enterprise value
68.32M73.09M39.43M116.6M157.96M
P/E ratio
-5.1-6.39-4.52-11.24-12.61
Price to sales ratio
64.16306.350283.840.07
POCF ratio
-16.7-16.15-7.41-29.47-26.2
PFCF ratio
-16.55-15.58-7.4-29.47-26.2
P/B Ratio
13.1314.635.234.15.86
PTB ratio
13.1314.635.234.15.86
EV to sales
61.41292.380227.510.06
Enterprise value over EBITDA
-5.13-6.9-4.05-8.91-11.42
EV to operating cash flow
-15.99-15.42-6.38-23.62-24.33
EV to free cash flow
-15.85-14.87-6.37-23.62-24.33
Earnings yield
-0.2-0.16-0.22-0.09-0.08
Free cash flow yield
-0.06-0.06-0.14-0.03-0.04
Debt to equity
000.010.010.01
Debt to assets
000.010.010.01
Net debt to EBITDA
0.230.330.652.210.88
Current ratio
4.384.117.8828.3414.83
Interest coverage
0000-133.41
Income quality
0.30.40.610.380.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.2122.65013.80
Research and developement to revenue
6.1221.89012.080
Intangibles to total assets
0.130000
Capex to operating cash flow
0.010.04000
Capex to revenue
-0.03-0.7000
Capex to depreciation
-0.11-0.38-0.1800
Stock based compensation to revenue
822.85015.720
Graham number
2.351.92.013.563.09
ROIC
-2.69-2.22-1.13-0.36-0.46
Return on tangible assets
-2.49-1.91-1.07-0.36-0.44
Graham Net
0.220.160.291.20.9
Working capital
4.27M4.61M8.18M34.73M28.16M
Tangible asset value
4.35M4.81M8.26M34.77M28.2M
Net current asset value
4.27M4.61M8.18M34.51M27.99M
Invested capital
000.010.010.01
Average receivables
033.26K34.38K1.12K0
Average payables
531.17K583.91K409.09K184.28K200.6K
Average inventory
0-1.18M-2.5M-1.32M0
Days sales outstanding
097.13000
Days payables outstanding
276.461.29K0129.120
Days of inventory on hand
0-5.16K000
Receivables turnover
03.76000
Payables turnover
1.320.2802.830
Inventory turnover
0-0.07000
ROE
-2.58-2.29-1.16-0.37-0.46
Capex per share
0-0.01000

Quarterly Fundamentals Overview

Last date of statement is 2023-07-31 for Q3

Metric History 2022-07-312022-10-312023-01-312023-04-30 2023-07-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
081.2900.010
Net income per share
-0.09-0.11-0.07-0.07-0.08
Operating cash flow per share
-0.05-0.05-0.06-0.03-0.05
Free cash flow per share
-0.05-0.05-0.06-0.03-0.05
Cash per share
1.040.980.90.870.82
Book value per share
1.040.960.90.870.82
Tangible book value per share
1.010.930.870.840.79
Share holders equity per share
1.040.960.90.870.82
Interest debt per share
0.010.010.0100.01
Market cap
118.15M170.09M135.12M123.72M111.2M
Enterprise value
94.13M157.96M125.54M118.3M108.19M
P/E ratio
-10.93-12.52-15.93-15.2-11.07
Price to sales ratio
00.070589.140
POCF ratio
-84.63-106.78-67.97-153.31-76.95
PFCF ratio
-84.63-106.78-67.97-153.31-76.95
P/B Ratio
3.735.864.864.614.36
PTB ratio
3.735.864.864.614.36
EV to sales
00.060563.320
Enterprise value over EBITDA
-33.77-43.9-49.33-46.43-38.19
EV to operating cash flow
-67.43-99.16-63.15-146.59-74.87
EV to free cash flow
-67.43-99.16-63.15-146.59-74.87
Earnings yield
-0.02-0.02-0.02-0.02-0.02
Free cash flow yield
-0.01-0.01-0.01-0.01-0.01
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
8.623.373.762.131.06
Current ratio
22.0114.8322.8117.8314.22
Interest coverage
-127.14-45.11-12.6510.120
Income quality
0.50.450.840.350.57
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0007.670
Research and developement to revenue
0004.750
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0005.720
Graham number
1.441.551.181.131.23
ROIC
-0.08-0.12-0.08-0.08-0.11
Return on tangible assets
-0.08-0.11-0.07-0.07-0.09
Graham Net
0.990.90.850.820.77
Working capital
30.87M28.16M26.87M25.87M24.54M
Tangible asset value
30.91M28.2M26.91M25.91M24.59M
Net current asset value
30.68M27.99M26.71M25.72M24.41M
Invested capital
0.010.010.010.010.01
Average receivables
0073.5K201.5K295K
Average payables
160K246K187.5K152.5K144.5K
Average inventory
00000
Days sales outstanding
000109.710
Days payables outstanding
000109.010
Days of inventory on hand
00000
Receivables turnover
0000.820
Payables turnover
0000.830
Inventory turnover
00000
ROE
-0.09-0.12-0.08-0.08-0.1
Capex per share
00000

ANIX Frequently Asked Questions

What is Anixa Biosciences, Inc. stock symbol ?

Anixa Biosciences, Inc. is a US stock , located in San jose of Ca and trading under the symbol ANIX

Is Anixa Biosciences, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8

What is ANIX stock prediction ?

What is Anixa Biosciences, Inc. stock quote today ?

Anixa Biosciences, Inc. stock price is $4.1798 today.

Is Anixa Biosciences, Inc. stock public?

Yes, Anixa Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap